Ebastine Sandoz: Uses, Dosage & Side Effects
A second-generation antihistamine orodispersible tablet for the symptomatic relief of allergic rhinitis and chronic idiopathic urticaria
Ebastine Sandoz is a prescription medication containing ebastine 10 mg, a second-generation, non-sedating antihistamine used for the symptomatic treatment of allergic rhinitis (both seasonal and perennial) and chronic idiopathic urticaria (hives). The orodispersible tablet formulation dissolves rapidly on the tongue without water, offering a convenient option for patients who have difficulty swallowing conventional tablets. Ebastine works by selectively blocking peripheral histamine H1 receptors, thereby reducing allergy symptoms such as sneezing, nasal itching, runny nose, watery eyes, and skin itching. Taken once daily, Ebastine Sandoz provides 24-hour symptom relief with a low risk of sedation and minimal anticholinergic effects.
Quick Facts: Ebastine Sandoz
Key Takeaways
- Ebastine Sandoz contains 10 mg of ebastine, a second-generation antihistamine that selectively blocks H1 histamine receptors to relieve allergy symptoms including sneezing, runny nose, itchy eyes, and hives with once-daily dosing.
- The orodispersible tablet dissolves on the tongue without water, making it especially convenient for patients who have difficulty swallowing tablets or who need to take their medication on the go.
- At the recommended 10 mg dose, ebastine has a very low incidence of sedation comparable to placebo, making it suitable for use during daily activities including driving (with initial caution).
- Important drug interactions exist with strong CYP3A4 inhibitors (such as ketoconazole and erythromycin), which can increase ebastine levels and potentially prolong the QT interval — always inform your doctor about all medications you take.
- Ebastine Sandoz should be stored below 30°C in its original packaging to protect from moisture, and the orodispersible tablet should be handled with dry hands and peeled from the blister rather than pushed through.
What Is Ebastine Sandoz and What Is It Used For?
Ebastine Sandoz contains the active substance ebastine, which belongs to the class of second-generation (non-sedating) antihistamines. Unlike first-generation antihistamines such as diphenhydramine, chlorphenamine, and hydroxyzine, which readily cross the blood-brain barrier and cause significant drowsiness and cognitive impairment, ebastine was specifically designed to act primarily at peripheral H1 receptors with minimal central nervous system penetration. This pharmacological profile translates into effective allergy symptom relief with a substantially reduced risk of sedation, making it suitable for daytime use and compatible with daily activities that require alertness.
Ebastine itself is a prodrug: after oral administration, it is rapidly absorbed from the gastrointestinal tract and undergoes extensive first-pass hepatic metabolism by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. This metabolic process converts ebastine into its principal and pharmacologically active metabolite, carebastine (also known as ebastine carboxylic acid). Carebastine is a potent, selective, and long-acting histamine H1-receptor antagonist that accounts for essentially all of the clinical antihistaminic activity of the drug. The fact that ebastine is a prodrug has important implications for drug interactions, as substances that inhibit CYP3A4 can affect the conversion of ebastine to carebastine and alter plasma drug levels.
Histamine is a key chemical mediator released from mast cells and basophils during allergic reactions. When an allergen (such as pollen, dust mites, or animal dander) enters the body and binds to IgE antibodies on the surface of mast cells, it triggers degranulation and the release of histamine along with other inflammatory mediators. Histamine then binds to H1 receptors located on various cell types, including vascular endothelial cells, airway smooth muscle cells, sensory nerve endings, and epithelial cells in the nasal mucosa. This binding triggers a cascade of allergic symptoms: vasodilation and increased vascular permeability (leading to nasal congestion and rhinorrhea), mucus hypersecretion, stimulation of sensory nerve endings (causing itching and sneezing), and smooth muscle contraction in the airways. By selectively and reversibly blocking the H1 receptor, carebastine prevents histamine from initiating this cascade, thereby providing relief from the hallmark symptoms of allergic conditions.
Ebastine Sandoz is indicated for the symptomatic treatment of two primary allergic conditions:
- Allergic rhinitis: This includes both seasonal allergic rhinitis (hay fever), triggered by outdoor allergens such as tree, grass, and weed pollens, and perennial allergic rhinitis, caused by year-round indoor allergens such as house dust mites, mold spores, and pet dander. Symptoms include sneezing, nasal itching, rhinorrhea (runny nose), nasal congestion, and ocular symptoms (itchy, watery, red eyes). The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines, developed in collaboration with the WHO, classify allergic rhinitis by both duration (intermittent or persistent) and severity (mild or moderate-severe). Second-generation antihistamines such as ebastine are recommended as first-line pharmacotherapy for mild-to-moderate allergic rhinitis.
- Chronic idiopathic urticaria (CIU): Also referred to as chronic spontaneous urticaria (CSU), this condition is characterized by the recurrent appearance of itchy wheals (hives) with or without angioedema, occurring for six weeks or more without an identifiable external trigger. The EAACI/GA2LEN/EDF/WAO international urticaria guidelines recommend second-generation H1 antihistamines as the first-line treatment for chronic urticaria, with the option of updosing up to four times the standard dose if the initial dose does not provide adequate symptom control.
The orodispersible tablet formulation of Ebastine Sandoz offers a distinct advantage over conventional tablets. The tablet is designed to disintegrate rapidly when placed on the tongue, typically within seconds, without the need for water. This makes it particularly convenient for patients who have difficulty swallowing tablets (dysphagia), for elderly patients, for children (when prescribed by a physician), and for anyone who needs to take their medication in situations where water may not be readily available. The orodispersible form has been shown to have bioequivalence to the standard oral tablet, meaning it delivers the same therapeutic dose and achieves comparable blood levels of carebastine.
Multiple randomized, double-blind, placebo-controlled clinical trials have demonstrated the efficacy of ebastine 10 mg in reducing the total symptom score (TSS) of allergic rhinitis, including sneezing, rhinorrhea, nasal itching, and ocular symptoms. In comparative studies with other second-generation antihistamines (cetirizine, loratadine, fexofenadine), ebastine 10 mg showed comparable efficacy with a particularly favorable sedation profile. For chronic urticaria, ebastine 10–20 mg significantly reduced pruritus (itch) scores, wheal number, and wheal size compared with placebo, with improvements maintained over treatment periods of 4–12 weeks.
What Should You Know Before Taking Ebastine Sandoz?
Contraindications
Ebastine Sandoz must not be taken by individuals who have a known hypersensitivity (allergy) to ebastine or to any of the excipients contained in the formulation. The orodispersible tablet contains inactive ingredients such as mannitol, crospovidone, microcrystalline cellulose, magnesium stearate, and a flavoring agent. Patients with known intolerances to any of these substances should not take this medication. If you have experienced an allergic reaction to ebastine in the past, including symptoms such as skin rash, itching, swelling of the face or throat, or difficulty breathing, you should not take Ebastine Sandoz and should inform your doctor immediately.
Ebastine is also contraindicated in patients with severe hepatic (liver) impairment. Because ebastine is a prodrug that requires hepatic metabolism via CYP3A4 for conversion to its active metabolite carebastine, severe liver dysfunction can significantly alter the drug's pharmacokinetics. In patients with hepatic impairment, plasma levels of unchanged ebastine may be elevated while the formation of carebastine may be impaired, potentially leading to an increased risk of adverse effects, particularly cardiac effects related to QT prolongation.
Warnings and Precautions
At higher than recommended doses or when combined with strong CYP3A4 inhibitors (such as ketoconazole or erythromycin), ebastine may prolong the QT interval on the electrocardiogram (ECG). This can increase the risk of serious cardiac arrhythmias. Do not exceed the recommended dose of 10 mg daily, and inform your doctor about all medications you are taking, especially antifungal agents, macrolide antibiotics, and HIV protease inhibitors.
Before starting Ebastine Sandoz, discuss the following conditions and risk factors with your healthcare provider:
- Cardiac conditions: Patients with a known history of QT interval prolongation (either congenital long QT syndrome or acquired QT prolongation from other medications), clinically significant bradycardia, uncompensated heart failure, or electrolyte disturbances (particularly hypokalemia or hypomagnesemia) should exercise particular caution. At the standard 10 mg dose, ebastine does not cause clinically significant QT prolongation in healthy individuals. However, at supratherapeutic doses (40–100 mg) or when plasma levels are elevated due to CYP3A4 inhibition, QT prolongation has been observed in thorough QT studies.
- Hepatic impairment: Patients with mild-to-moderate liver disease may have altered metabolism of ebastine. Your doctor may need to adjust the dose or choose an alternative antihistamine. Ebastine is contraindicated in severe hepatic impairment.
- Renal impairment: No dose adjustment is generally required in patients with renal impairment, as ebastine and carebastine are eliminated primarily through hepatic metabolism. However, carebastine is partially excreted renally (approximately 66%), and severe renal impairment may warrant monitoring.
- Elderly patients: Ebastine can be used in elderly patients. Clinical studies have not demonstrated age-related differences in safety or efficacy. However, elderly patients may have reduced hepatic function and should be monitored accordingly.
- Phenylketonuria: Check the specific product labeling to determine whether the orodispersible tablet contains aspartame, a source of phenylalanine. Patients with phenylketonuria (PKU) should be informed if aspartame is present.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, you should consult your doctor before taking Ebastine Sandoz. There are limited clinical data from the use of ebastine in pregnant women. Animal reproductive toxicity studies have not demonstrated direct harmful effects on embryo-fetal development at therapeutic doses; however, at very high doses (approximately 40 times the human dose in rats), some evidence of fetotoxicity has been observed. As with most medications, ebastine should be avoided during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the fetus. This is especially important during the first trimester, when organogenesis occurs.
It is not known whether ebastine or its active metabolite carebastine is excreted in human breast milk. Animal studies have shown excretion of ebastine and metabolites in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for adverse effects in the nursing infant, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother. If an antihistamine is needed during breastfeeding, your doctor may recommend alternatives with more established safety data in lactation, such as loratadine or cetirizine.
Driving and Operating Machinery
At the recommended dose of 10 mg, ebastine does not cause clinically significant impairment of psychomotor function or driving performance in the majority of patients. Multiple controlled studies, including standardized driving tests and cognitive function assessments, have shown that ebastine 10 mg does not differ significantly from placebo in its effects on driving ability, reaction time, or attention. However, individual responses to medications can vary, and some patients may experience mild drowsiness, particularly when first initiating treatment. It is advisable to assess your individual response to Ebastine Sandoz before driving or operating machinery, especially during the first days of therapy.
Alcohol
Clinical interaction studies have demonstrated that ebastine 10 mg does not significantly potentiate the cognitive or psychomotor effects of moderate alcohol consumption. This is an important distinction from first-generation antihistamines, which markedly enhance alcohol-related sedation and impairment. Nevertheless, alcohol independently affects alertness and coordination, and it is generally recommended to exercise moderation and caution when combining any medication with alcohol.
How Does Ebastine Sandoz Interact with Other Drugs?
Because ebastine is a prodrug that undergoes extensive first-pass hepatic metabolism via the cytochrome P450 3A4 (CYP3A4) enzyme system, any drug that significantly inhibits or induces CYP3A4 can alter the plasma concentrations of ebastine and its active metabolite carebastine. This pharmacokinetic interaction is the most clinically important consideration when prescribing ebastine alongside other medications. Understanding these interactions is essential for safe use of the drug.
When CYP3A4 is inhibited, the normal metabolic conversion of ebastine to carebastine is impaired. This leads to increased plasma levels of the parent compound (ebastine) and decreased levels of the active metabolite (carebastine). Elevated levels of unchanged ebastine are of clinical concern because, unlike carebastine, the parent compound has been shown to have a greater potential for prolonging the cardiac QT interval at high concentrations. In pharmacokinetic interaction studies, co-administration of ketoconazole (a potent CYP3A4 inhibitor) with ebastine resulted in approximately a 16-fold increase in peak plasma concentration (Cmax) and a 40-fold increase in the area under the curve (AUC) of unchanged ebastine, along with a modest but statistically significant QTc prolongation. Similarly, erythromycin caused approximately a 2- to 3-fold increase in ebastine plasma levels.
Major Interactions
| Interacting Drug | Drug Class | Mechanism | Clinical Effect |
|---|---|---|---|
| Ketoconazole | Azole antifungal | Potent CYP3A4 inhibitor | Markedly increased ebastine levels; QTc prolongation risk |
| Itraconazole | Azole antifungal | Potent CYP3A4 inhibitor | Significantly increased ebastine levels; QTc prolongation risk |
| Erythromycin | Macrolide antibiotic | Moderate CYP3A4 inhibitor | Increased ebastine levels; potential QTc prolongation |
| Clarithromycin | Macrolide antibiotic | Potent CYP3A4 inhibitor | Increased ebastine levels; potential QTc prolongation |
| Ritonavir / Cobicistat | HIV protease inhibitor booster | Potent CYP3A4 inhibitor | Markedly increased ebastine levels; cardiac risk |
| Other QT-prolonging drugs | Various (antiarrhythmics, antipsychotics, fluoroquinolones) | Additive QT prolongation | Combined QTc prolongation; increased risk of torsades de pointes |
Minor Interactions and Considerations
| Interacting Drug | Drug Class | Mechanism | Clinical Effect |
|---|---|---|---|
| Rifampicin | Antimycobacterial | Potent CYP3A4 inducer | Reduced ebastine and carebastine levels; decreased efficacy |
| Carbamazepine | Anticonvulsant | CYP3A4 inducer | Potentially reduced antihistaminic effect |
| St. John's Wort | Herbal supplement | CYP3A4 inducer | Potentially reduced antihistaminic effect |
| Grapefruit juice | Food interaction | Intestinal CYP3A4 inhibitor | Modestly increased ebastine absorption; generally not clinically significant at normal intake |
| Diazepam | Benzodiazepine | Pharmacodynamic (additive CNS depression) | Potential additive sedation; no pharmacokinetic interaction demonstrated |
It is important to inform your healthcare provider and pharmacist about all medications you are taking, including prescription drugs, over-the-counter products, herbal supplements, and vitamins. This allows them to screen for potential interactions and adjust your treatment plan if necessary. If you need an antifungal treatment while taking ebastine, your doctor may recommend temporarily stopping ebastine or switching to an antihistamine that is not metabolized by CYP3A4, such as cetirizine or fexofenadine.
Ebastine can be taken with or without food. Food does not significantly affect the overall bioavailability (total absorption) of ebastine, although it may slightly delay the time to peak plasma concentrations. Large amounts of grapefruit juice may modestly inhibit intestinal CYP3A4 and increase ebastine absorption, but this effect is generally not clinically significant at normal dietary intake. There is no specific requirement to avoid grapefruit when taking the standard 10 mg dose.
What Is the Correct Dosage of Ebastine Sandoz?
Adults
Adults (18 years and older)
The recommended dose is 10 mg (one orodispersible tablet) once daily. The tablet should be placed on the tongue, where it will disintegrate rapidly, and then swallowed with saliva. No water is required. The tablet can be taken at any time of day, with or without food, though taking it at the same time each day helps maintain consistent blood levels. For chronic conditions such as perennial allergic rhinitis or chronic urticaria, treatment may be continued for extended periods as directed by your doctor.
In some countries, a 20 mg dose of ebastine is available for patients with more severe symptoms or those who have an inadequate response to the 10 mg dose. However, the Ebastine Sandoz orodispersible tablet is available in the 10 mg strength. Do not take two tablets to achieve a 20 mg dose unless specifically instructed to do so by your doctor, as the 20 mg dose requires medical supervision and ECG monitoring in some clinical settings.
Children and Adolescents
Adolescents (12–17 years)
The same dose as adults: 10 mg (one orodispersible tablet) once daily. The safety and efficacy profile in adolescents is considered similar to that in adults based on clinical data and pharmacokinetic modeling.
Children (6–11 years)
Ebastine may be prescribed to children aged 6–11 years at a reduced dose, typically 5 mg once daily, using an appropriate formulation (e.g., oral solution or half-tablet where scored tablets are available). The Ebastine Sandoz orodispersible 10 mg tablet is generally not recommended for children under 12 unless specifically prescribed by a pediatrician, as the 10 mg tablet cannot be accurately halved. Always follow your doctor's specific dosing instructions for children.
Children under 6 years
Ebastine is not recommended for children under 6 years of age due to insufficient safety and efficacy data in this age group.
Elderly Patients
Elderly (65 years and older)
No specific dose adjustment is required in elderly patients. Clinical studies have not identified clinically significant differences in pharmacokinetics or safety between elderly and younger adult patients. However, hepatic function may be reduced in elderly patients, and this should be taken into account. Elderly patients with known liver impairment may require medical evaluation before starting treatment.
Hepatic and Renal Impairment
Hepatic Impairment
In patients with mild-to-moderate hepatic impairment, the dose should not exceed 10 mg once daily, and treatment should be initiated with caution under medical supervision. Ebastine is contraindicated in severe hepatic impairment because the altered metabolism may lead to elevated levels of the parent compound and increased cardiac risk.
Renal Impairment
No dose adjustment is required for patients with renal impairment. However, patients with severe renal failure should be monitored, as the renal excretion of carebastine may be reduced.
Missed Dose
If you forget to take your daily dose of Ebastine Sandoz, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. Taking ebastine consistently at the same time each day can help minimize the chance of missed doses and ensures steady-state therapeutic blood levels are maintained.
Overdose
If you suspect an overdose of Ebastine Sandoz, contact your local poison control center or emergency department immediately. While experience with ebastine overdose in humans is limited, symptoms may include excessive drowsiness, dry mouth, headache, and potentially cardiac effects including QT prolongation and arrhythmias at very high doses. Treatment is supportive and symptomatic. There is no specific antidote for ebastine. Activated charcoal may be considered if the overdose is recent. ECG monitoring is recommended due to the potential for QT prolongation at high doses.
With dry hands, peel back the foil backing of the blister pack — do not push the tablet through the foil, as this may cause it to crumble. Place the tablet on your tongue and allow it to disintegrate. The tablet will dissolve within seconds. You can then swallow with saliva; no water is needed. If you prefer, you may take a sip of water after the tablet has dissolved. The orodispersible tablet provides the same therapeutic effect as a conventional swallowed tablet.
What Are the Side Effects of Ebastine Sandoz?
Like all medicines, Ebastine Sandoz can cause side effects, although not everybody gets them. In controlled clinical trials involving thousands of patients, ebastine 10 mg demonstrated an adverse event profile comparable to placebo. The most commonly reported adverse effects were mild, transient, and generally did not require discontinuation of treatment. The following side effects have been reported during clinical trials and post-marketing surveillance, organized by their frequency of occurrence according to standard MedDRA conventions.
Common
May affect up to 1 in 10 people
- Headache
- Somnolence (drowsiness)
- Dry mouth
Uncommon
May affect up to 1 in 100 people
- Dizziness
- Nausea
- Abdominal pain
- Dyspepsia (indigestion)
- Insomnia (difficulty sleeping)
- Rhinitis (nasal symptoms unrelated to allergy)
- Pharyngitis (sore throat)
- Fatigue
- Epistaxis (nosebleed)
Rare
May affect up to 1 in 1,000 people
- Palpitations
- Tachycardia (rapid heart rate)
- Skin rash
- Urticaria (hives) as an adverse drug reaction
- Pruritus (itching) unrelated to the treated condition
- Elevated liver enzymes (transaminases)
Not Known
Frequency cannot be estimated from available data
- Anaphylaxis and severe allergic reactions (very rare post-marketing reports)
- Angioedema (swelling of face, lips, tongue, or throat)
- QT prolongation (observed at supratherapeutic doses or with CYP3A4 inhibitors)
- Hepatitis (extremely rare)
- Menstrual disturbances (isolated reports)
It is important to contextualize these side effects. In head-to-head comparisons with other second-generation antihistamines, ebastine 10 mg consistently demonstrated an incidence of somnolence that was not statistically different from placebo and comparable to or lower than that of loratadine 10 mg and cetirizine 10 mg. The particularly low rate of CNS side effects is attributable to ebastine's limited penetration of the blood-brain barrier and the high peripheral selectivity of its active metabolite carebastine for the H1 receptor.
Regarding cardiac safety, extensive clinical and post-marketing data confirm that ebastine at the recommended dose of 10 mg does not cause clinically relevant QTc prolongation. Thorough QT studies (as required by ICH E14 guidelines) demonstrated that ebastine 10 mg and 20 mg do not prolong the QTc interval beyond established thresholds of clinical concern. QTc prolongation has only been observed at supratherapeutic doses (60–100 mg) or when plasma levels of the parent compound are markedly elevated through CYP3A4 inhibition. This reinforces the importance of adhering to the prescribed dose and avoiding concurrent use with potent CYP3A4 inhibitors.
Stop taking Ebastine Sandoz and seek immediate medical help if you experience: difficulty breathing or swallowing; swelling of the face, lips, tongue, or throat; severe skin rash or hives with fever; rapid or irregular heartbeat accompanied by dizziness or fainting; or yellowing of the skin or eyes (jaundice). These symptoms may indicate a serious allergic reaction or a rare but significant adverse effect requiring prompt medical evaluation.
If you experience any side effects not listed here, or if any of the listed side effects become troublesome or persistent, consult your doctor or pharmacist. You can also report side effects to your national pharmacovigilance authority (e.g., the Yellow Card Scheme in the UK, MedWatch in the US, or the EMA's EudraVigilance system in the EU). Reporting helps authorities monitor the ongoing safety of medicines.
How Should You Store Ebastine Sandoz?
Proper storage of Ebastine Sandoz is essential to ensure the medication retains its full potency and safety throughout its shelf life. Orodispersible tablets are particularly sensitive to moisture because they are formulated to disintegrate rapidly when exposed to liquid, including humidity in the air. The following storage guidelines should be carefully observed:
- Temperature: Store at a temperature below 30°C (86°F). Do not refrigerate or freeze the tablets, as this may affect the disintegration properties of the orodispersible formulation.
- Moisture protection: Keep the tablets in their original blister packaging until immediately before use. The blister pack provides an essential moisture barrier. Do not transfer the tablets to a pill organizer or other container, as exposure to ambient humidity can cause premature disintegration or degradation.
- Light: Protect from direct sunlight and store in a cool, dry place.
- Handling: When removing a tablet from the blister, peel back the foil carefully with dry hands. Do not push the tablet through the foil, as the fragile orodispersible tablet may crumble or break.
- Children: Keep this medicine out of the sight and reach of children, stored securely in a location where young children cannot access it.
- Expiry date: Do not use Ebastine Sandoz after the expiry date stated on the blister and carton (EXP). The expiry date refers to the last day of that month.
- Disposal: Do not dispose of unused or expired medicines via household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer use. These measures help to protect the environment and prevent accidental exposure.
If a tablet has been accidentally exposed to moisture and appears damaged, soft, discolored, or has an unusual odor, do not take it. Discard the affected tablet safely and use a fresh one from the blister pack. If you notice any changes in the appearance of the tablets in an unopened blister (e.g., discoloration, moisture inside the blister), do not use them and consult your pharmacist.
What Does Ebastine Sandoz Contain?
Understanding the full composition of your medication is important, particularly if you have known allergies or intolerances to specific substances. The following provides a detailed breakdown of the active and inactive ingredients in Ebastine Sandoz orodispersible tablets:
Active Ingredient
Each orodispersible tablet contains 10 mg of ebastine. Ebastine is a white to off-white crystalline powder with the chemical name 4-(4-benzhydryloxy-1-piperidyl)-1-(4-tert-butylphenyl)butan-1-one. Its molecular formula is C32H39NO2 and it has a molecular weight of approximately 469.66 g/mol. Ebastine is practically insoluble in water but soluble in organic solvents, which is why it requires specific formulation technology to produce an orodispersible dosage form.
Inactive Ingredients (Excipients)
The orodispersible tablet contains the following excipients, which serve specific formulation functions:
- Mannitol: A sugar alcohol used as a sweetening agent and as a bulking agent that contributes to the pleasant taste and rapid disintegration of the orodispersible tablet.
- Microcrystalline cellulose: A pharmaceutical-grade cellulose derivative used as a binder and filler that helps maintain the structural integrity of the tablet.
- Crospovidone: A super-disintegrant that enables the rapid breakup of the tablet when it comes into contact with saliva on the tongue, facilitating the fast disintegration characteristic of the orodispersible formulation.
- Magnesium stearate: A lubricant used in the tablet manufacturing process to prevent the tablet mixture from sticking to the machinery during compression.
- Flavoring agents: Added to provide a pleasant taste, improving patient acceptability and compliance, especially important for a tablet that dissolves in the mouth.
If you have phenylketonuria (PKU), lactose intolerance, or any other known sensitivity to pharmaceutical excipients, carefully read the specific product labeling provided with your medication or consult your pharmacist. The exact excipient composition may vary slightly between different manufacturers and market formulations. Ebastine Sandoz orodispersible tablets are lactose-free and gluten-free, making them suitable for patients with lactose intolerance or celiac disease.
Appearance
Ebastine Sandoz 10 mg orodispersible tablets are typically white to off-white, round, flat-faced tablets. They may have a characteristic mild flavor from the flavoring agents. The tablets are packaged in aluminum/aluminum blister packs designed to protect against moisture, in cartons containing 10, 20, or 30 tablets (not all pack sizes may be marketed in every country).
Frequently Asked Questions About Ebastine Sandoz
Ebastine Sandoz is a second-generation antihistamine used for the symptomatic treatment of allergic rhinitis (hay fever), including seasonal and perennial forms, and chronic idiopathic urticaria (hives). It contains 10 mg of ebastine as an orodispersible tablet that dissolves on the tongue without water. It relieves sneezing, runny nose, itchy and watery eyes, nasal congestion, and skin itching associated with allergic conditions.
Ebastine Sandoz is classified as a non-sedating (second-generation) antihistamine, meaning it has a significantly lower risk of causing drowsiness compared to first-generation antihistamines. At the recommended 10 mg dose, the incidence of somnolence in clinical trials was comparable to placebo. However, some individuals may still experience mild drowsiness, particularly when first starting treatment, and caution is advised when driving or operating machinery until you know how the medication affects you.
Place the orodispersible tablet on your tongue and allow it to dissolve; it will disintegrate rapidly without the need for water. You can then swallow it with saliva. The tablet should be taken once daily, with or without food. Do not push the tablet through the foil blister; instead, peel back the foil backing carefully. Handle the tablet with dry hands, as moisture may cause it to crumble.
Ebastine Sandoz should not be used during pregnancy unless clearly necessary and prescribed by a doctor. There are limited data from the use of ebastine in pregnant women. Animal studies have not shown direct harmful effects at therapeutic doses. However, as a precaution, it is recommended to avoid ebastine during pregnancy, especially during the first trimester. Consult your doctor before taking this medication if you are pregnant, think you may be pregnant, or are planning to become pregnant.
Clinical studies have shown that ebastine at the recommended 10 mg dose does not significantly potentiate the sedative effects of alcohol, unlike first-generation antihistamines. However, it is generally advisable to exercise caution when combining any antihistamine with alcohol, as alcohol can independently cause drowsiness. If you choose to consume alcohol while taking Ebastine Sandoz, do so in moderation and monitor how you feel before driving or operating machinery.
Ebastine, cetirizine, and loratadine are all second-generation antihistamines. Key differences include: ebastine is a prodrug metabolized to carebastine via CYP3A4, while cetirizine is the active metabolite of hydroxyzine and loratadine is metabolized to desloratadine. Ebastine has a particularly low incidence of sedation comparable to loratadine and generally lower than cetirizine. All three are effective for allergic rhinitis and urticaria, but individual response may vary. The orodispersible formulation offers convenience for patients who have difficulty swallowing tablets or lack access to water.
References
- European Medicines Agency (EMA). Ebastine — Summary of Product Characteristics. Last updated 2024. Available from EMA product database.
- Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63 Suppl 86:8-160.
- Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766.
- Rico S, Antonijoan RM, Barbanoj MJ. Ebastine in the light of CONGA recommendations for development of third-generation antihistamines. J Asthma Allergy. 2009;2:73-92.
- Sastre J. Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy. 2008;63 Suppl 89:1-20.
- Mattila MJ, Kuitunen T, Pletan Y. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects. Eur J Clin Pharmacol. 1992;43(2):179-184.
- Hashizume T, Iijima K, Yamashita T, et al. Effect of ketoconazole on the pharmacokinetics and electrocardiographic effects of ebastine. Clin Pharmacol Ther. 2002;72(6):592-602.
- British National Formulary (BNF). Ebastine. National Institute for Health and Care Excellence (NICE). Updated 2025. Available from bnf.nice.org.uk.
- World Health Organization (WHO). Model List of Essential Medicines. 23rd edition, 2023. Antihistamines section.
- Moss AJ, Morganroth J. Cardiac QT-prolongation and antihistamines: A review of clinical and experimental evidence. Drug Saf. 2001;24(5):323-338.
Editorial Team
Medical Writer
iMedic Medical Editorial Team — Specialists in clinical pharmacology and allergy medicine with expertise in evidence-based drug information
Medical Reviewer
iMedic Medical Review Board — Independent panel of board-certified physicians reviewing content according to EAACI, ARIA, and GRADE frameworks
Pharmacological Advisor
Clinical pharmacology specialist with expertise in antihistamine pharmacokinetics, drug interactions, and cardiac safety assessment
Accessibility Lead
WCAG 2.2 AAA certified accessibility specialist ensuring all content meets the highest international accessibility standards
Editorial Standards: All medical content is written according to the GRADE evidence framework, reviewed by board-certified specialists, and updated regularly to reflect the latest clinical guidelines and safety data. We maintain strict editorial independence with no pharmaceutical company funding or influence. Read our full editorial standards.